178 related articles for article (PubMed ID: 29526968)
1. Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis.
Kudo F; Watanabe Y; Iwai Y; Miwa C; Nagai Y; Ota H; Yabe H; Demitsu T; Hagiwara K; Koyama N; Koyama S
Intern Med; 2018 Aug; 57(15):2217-2221. PubMed ID: 29526968
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab-Induced Severe Akathisia in an Advanced Lung Cancer Patient.
Abe J; Sato T; Tanaka R; Okazaki T; Takahashi S
Am J Case Rep; 2016 Nov; 17():880-882. PubMed ID: 27893699
[TBL] [Abstract][Full Text] [Related]
3. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report.
Ikeuchi K; Okuma Y; Tabata T
Lung Cancer; 2016 Sep; 99():148-50. PubMed ID: 27565931
[TBL] [Abstract][Full Text] [Related]
4. Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer.
Yasuda Y; Urata Y; Tohnai R; Ito S; Kawa Y; Kono Y; Hattori Y; Tsuda M; Sakuma T; Negoro S; Satouchi M
Intern Med; 2018 May; 57(9):1269-1272. PubMed ID: 29279482
[TBL] [Abstract][Full Text] [Related]
5. Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report.
Uenami T; Hosono Y; Ishijima M; Kanazu M; Akazawa Y; Yano Y; Mori M; Yamaguchi T; Yokota S
Lung Cancer; 2017 Jul; 109():42-44. PubMed ID: 28577948
[TBL] [Abstract][Full Text] [Related]
6. The Significant Antitumor Activity of Nivolumab in Lung Adenocarcinoma with Choriocarcinomatous Features.
Ochi M; Miyamoto S; Terada Y; Furuhata Y; Awano N; Izumo T; Ikushima S; Bae Y; Kumasaka T; Kunito H
Intern Med; 2018 Jun; 57(12):1773-1777. PubMed ID: 29434118
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
8. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H
World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749
[TBL] [Abstract][Full Text] [Related]
9. Dramatic Antitumor Activity of Nivolumab in Advanced HER2-Positive Lung Cancer.
Catania C; Passaro A; Rocco EG; Spitaleri G; Barberis M; Noberasco C; Signore ED; Travaini L; de Marinis F
Clin Lung Cancer; 2016 Sep; 17(5):e179-e183. PubMed ID: 27349506
[No Abstract] [Full Text] [Related]
10. Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1.
Iwata T; Yamamoto A; Hara K
J Thorac Oncol; 2017 Dec; 12(12):e205-e207. PubMed ID: 29169526
[No Abstract] [Full Text] [Related]
11. Isolated Adrenocorticotropin Deficiency due to Nivolumab-induced Hypophysitis in a Patient with Advanced Lung Adenocarcinoma: A Case Report and Literature Review.
Ohara N; Ohashi K; Fujisaki T; Oda C; Ikeda Y; Yoneoka Y; Hashimoto T; Hasegawa G; Suzuki K; Takada T
Intern Med; 2018 Feb; 57(4):527-535. PubMed ID: 29151505
[TBL] [Abstract][Full Text] [Related]
12. Partial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case report.
Pluchart H; Pinsolle J; Cohen J; Ferretti GR; Bedouch P; Giaj Levra M; Toffart AC; Moro-Sibilot D
J Med Case Rep; 2017 Jul; 11(1):183. PubMed ID: 28679408
[TBL] [Abstract][Full Text] [Related]
13. Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression.
Tanizaki J; Hayashi H; Kimura M; Tanaka K; Takeda M; Shimizu S; Ito A; Nakagawa K
Lung Cancer; 2016 Dec; 102():44-48. PubMed ID: 27987588
[TBL] [Abstract][Full Text] [Related]
14. IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma.
Kishi S; Minato M; Saijo A; Murakami N; Tamaki M; Matsuura M; Murakami T; Nagai K; Abe H; Nishioka Y; Doi T
Intern Med; 2018 May; 57(9):1259-1263. PubMed ID: 29279511
[TBL] [Abstract][Full Text] [Related]
15. Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade.
Läubli H; Hench J; Stanczak M; Heijnen I; Papachristofilou A; Frank S; Zippelius A; Stenner-Liewen F
J Immunother Cancer; 2017; 5():46. PubMed ID: 28642817
[TBL] [Abstract][Full Text] [Related]
16. The safety of nivolumab for the treatment of advanced non-small cell lung cancer.
Metro G; Ricciuti B; Brambilla M; Baglivo S; Soli I; Minenza E; Leonardi GC; D'arpino A; Colabrese D; Tazza M; Zicari D; Minotti V; Chiari R
Expert Opin Drug Saf; 2017 Jan; 16(1):101-109. PubMed ID: 27910704
[TBL] [Abstract][Full Text] [Related]
17. Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review.
Obara K; Masuzawa M; Amoh Y
J Dermatol; 2018 May; 45(5):587-591. PubMed ID: 29352490
[TBL] [Abstract][Full Text] [Related]
18. Severe Pneumonitis after Nivolumab Treatment Accompanied by Acute Pulmonary Embolism in a Patient with Lung Adenocarcinoma.
Liao JP; Nie LG; Que CL; Mu XD
Chin Med J (Engl); 2017 Nov; 130(22):2755-2756. PubMed ID: 29133768
[No Abstract] [Full Text] [Related]
19. Understanding immunotherapy for the treatment of non-small cell lung cancer.
Thomas R
Br J Nurs; 2016 Sep; 25(16):S12-7. PubMed ID: 27615536
[TBL] [Abstract][Full Text] [Related]
20. Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study.
Teraoka S; Fujimoto D; Morimoto T; Kawachi H; Ito M; Sato Y; Nagata K; Nakagawa A; Otsuka K; Uehara K; Imai Y; Ishida K; Fukuoka J; Tomii K
J Thorac Oncol; 2017 Dec; 12(12):1798-1805. PubMed ID: 28939128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
